Steven Keith Burke

CIK: 0001619834

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

SCYX

SCYNEXIS INC

Director

AKBA

Akebia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

SCYX
SCYNEXIS INC
Sep 18, 2026
Award(A)
Direct
5.8K shares-
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
21.6K shares at avg. $1.39$30K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
20.7K shares at avg. $1.39$29K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
25.4K shares at avg. $1.39$35K
AKBA
Akebia Therapeutics, Inc.
Jan 30, 2026
Award(A)
Direct
204K shares-
AKBA
Akebia Therapeutics, Inc.
Mar 3, 2025
Sale(S)
Direct
7.1K shares at avg. $1.83$13K
AKBA
Akebia Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
27.2K shares at avg. $2.10$57K
AKBA
Akebia Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
23.3K shares at avg. $2.10$49K
AKBA
Akebia Therapeutics, Inc.
Jan 31, 2025
Award(A)
Direct
194.9K shares-

		Type	Shares	Price		Ownership
Sep 18, 2026	SCYX SCYNEXIS INC	Award(A)	5,750	-	$0	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	21,582	$1.39	$29,999	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	20,701	$1.39	$28,774	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	25,375	$1.39	$35,271	Direct
Jan 30, 2026	AKBA Akebia Therapeutics, Inc.	Award(A)	204,000	-	$0	Direct
Mar 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	7,144	$1.83	$13,074	Direct
Feb 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	27,236	$2.10	$57,196	Direct
Feb 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	23,270	$2.10	$48,867	Direct
Jan 31, 2025	AKBA Akebia Therapeutics, Inc.	Award(A)	194,900	-	-	Direct

1-9 of 9 transactions

About Burke Steven Keith

Burke Steven Keith (SEC CIK 0001619834) files insider reports with the SEC as Director of SCYNEXIS INC (SCYX) and SVP, Chief Medical Officer of Akebia Therapeutics, Inc. (AKBA).

Signal8 holds 6 ownership filings by Burke Steven Keith (1 Form 3, 5 Form 4), filed between Feb 4, 2025 and Sep 22, 2026. Those filings report 9 transactions, from Jan 31, 2025 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Burke Steven Keith's filings is in JERSEY CITY, NJ.

Recent filings by Burke Steven Keith

Sep 18, 2026: Grant or award of SCYX shares (Form 4, code A).
Feb 2, 2026: Open-market sales of AKBA shares (3 lines, Form 4, code S).
Jan 30, 2026: Grant or award of AKBA shares (Form 4, code A).
Mar 3, 2025: Open-market sale of AKBA shares (Form 4, code S).
Feb 3, 2025: Open-market sales of AKBA shares (2 lines, Form 4, code S).

Other insiders filing for SCYNEXIS INC (SCYX)

Subramanian Sanjay, Chief Financial Officer
Tinmouth Brian Philippe, Officer
Macdonald Guy, Officer
ANIDO ARMANDO, Officer
HASTINGS DAVID C, Officer
HANHAM ANN, Officer

How to read Form 4 transaction codes